Equity Issuances

Envoy Medical, Inc. issued up to an aggregate of 9,022,572 shares of Common Stock of warrant to accredited and institutional investors named therein for $1.33 per share.

“(the “Registered Offering”) 3,007,524 shares (the “Shares”) of Class A common stock, par value $0.0001 per share, of the Company (“Common Stock”), at a purchase price of $1.33 per share. The Shares were offered pursuant to an effective shelf registration statement on Form S-3 (Registration No. 333-282474) and a related prospectus supplement filed with”

Envoy Medical, Inc. issued 3,007,524 shares of common stock to accredited and institutional investors named therein for $1.33 per share.

“(the “Registered Offering”) 3,007,524 shares (the “Shares”) of Class A common stock, par value $0.0001 per share, of the Company (“Common Stock”), at a purchase price of $1.33 per share. The Shares were offered pursuant to an effective shelf registration statement on Form S-3 (Registration No. 333-282474) and a related prospectus supplement filed with”

Airship AI Holdings, Inc. issued 2,702,702 shares of warrant to the Holder for $9,729,729 aggregate gross proceeds.

“price per share of $6.20 (the “Inducement Warrants”). The aggregate gross proceeds to be received from the exercise of the Existing Warrants is expected to be approximately $9,729,729, before deducting financial advisory fees. The Company intends to use the net proceeds from the exercise of the Existing Warrants for working capital and general corporate”

AI Infrastructure Acquisition Corp. issued 407,000 Units of unit to Sponsor and Maxim Partners LLC for $10.00 per Unit.

“Simultaneously with the closing of the IPO, pursuant to the Sponsor Subscription Agreement, the Company completed the private sale to the Sponsor of 269,000 Units, at a purchase price of $10.00 per Unit. Additionally, pursuant to the Maxim Subscription Agreement, the Company completed the private sale to Maxim Partners LLC (“Maxim Partners”) of 138,000 Units at a purchase price of $10.00 per Unit (such private sales, collectively, the “Private Placement”).”

APPLIED ENERGETICS, INC. issued 5,995,675 shares of common stock to accredited investors for $10,789,999 aggregate.

“On October 8, 2025, the company completed the placement of 5,995,675 shares of its common stock, par value, $0.001 per share, some of which were underlying pre-funded common stock purchase warrants, in a private sale to individual purchasers at a price of $1.80 per share (or $1.799 per underlying share for pre-funded warrants), for aggregate proceeds in the amount of $10,789,999.”

Karyopharm Therapeutics Inc. issued shares of common stock and warrants to purchase shares of common stock of common stock to holders of convertible notes for $24.25 million aggregate principal amount of the Company’s convertible notes due October 15, 2025.

“an exchange of $24.25 million aggregate principal amount of the Company’s convertible notes due October 15, 2025 for shares of common stock and warrants to purchase shares of common stock”

Karyopharm Therapeutics Inc. issued shares of common stock of common stock to holders of convertible notes for $15.0 million aggregate principal amount of the Company’s convertible notes due 2029.

“an exchange of $15.0 million aggregate principal amount of the Company’s convertible notes due 2029 for shares of common stock”

Karyopharm Therapeutics Inc. issued newly issued warrants to purchase an aggregate of 5,918,358 shares of common stock with an exercise price of $6.64 per share of warrant to accredited investors for $8.75 million.

“common stock and warrants to purchase shares of common stock; and (iv) a private placement of shares of common stock and warrants to purchase common stock for gross proceeds of $8.75 million. The Company intends to use the proceeds described above to pay transaction expenses and for general corporate purposes, including to support the Company’s ongoing and planned”

Karyopharm Therapeutics Inc. issued newly issued pre-funded warrants to purchase an aggregate of 2,913,136 shares of common stock of warrant to accredited investors for $8.75 million.

“common stock and warrants to purchase shares of common stock; and (iv) a private placement of shares of common stock and warrants to purchase common stock for gross proceeds of $8.75 million. The Company intends to use the proceeds described above to pay transaction expenses and for general corporate purposes, including to support the Company’s ongoing and planned”

Karyopharm Therapeutics Inc. issued 7,223,982 newly issued shares of common stock of common stock to accredited investors for $8.75 million.

“common stock and warrants to purchase shares of common stock; and (iv) a private placement of shares of common stock and warrants to purchase common stock for gross proceeds of $8.75 million. The Company intends to use the proceeds described above to pay transaction expenses and for general corporate purposes, including to support the Company’s ongoing and planned”

Vivakor, Inc. issued 82,500 shares of its common stock of common stock to non-affiliated accredited investor for issuance of a convertible promissory note in the aggregate principal amount of $647,500 in exchange for $550,000.

“reported, on August 12, 2025, the Company issued a convertible promissory note to a non-affiliated accredited investor (the “Holder”), in the aggregate principal amount of $647,500 in connection with a Securities Purchase Agreement entered into by and between the Company and the Holder (the “SPA”). The Company received $550,000 in exchange for issuing the”

Vivakor, Inc. issued 2,991,773 shares and 3,496,503 shares of the Company's common stock of common stock to J.J. Astor & Co. for conversion of $400,000 and $500,000 of the Principal Amount of the Initial Note.

“On October 2, 2025 and October 6, 2025, the Company received a Notices of Conversion from the Lender converting $400,000 and $500,000 of the Principal Amount of the Initial Note into 2,991,773 shares and 3,496,503 shares of the Company's common stock, respectively (together, the “Shares”).”

BioRestorative Therapies, Inc. issued up to an aggregate of 508,592 shares of the Company's common stock of warrant to several investors.

“the Company agreed to issue to the Purchasers unregistered warrants (the “Unregistered Warrants”) to purchase up to an aggregate of 508,592 shares of the Company’s common stock (the “Unregistered Warrant Shares”) at an exercise price of $2.75 per share.”

SPRUCE BIOSCIENCES, INC. issued pre-funded warrants to purchase up to 233,144 shares of Common Stock of warrant to certain institutional investors for purchase price for the Pre-Funded Warrants is $67.99.

“up to 233,144 shares of Common Stock (the “Pre-Funded Warrants”) in a private placement transaction (the “Private Placement”). The purchase price per share of Common Stock is $68.00 per share (the “Purchase Price”) and the purchase price for the Pre-Funded Warrants is $67.99, which equals the Purchase Price minus the $0.01 exercise price per Pre-Funded”

SPRUCE BIOSCIENCES, INC. issued 502,181 shares of common stock to certain institutional investors for $68.00 per share.

“up to 233,144 shares of Common Stock (the “Pre-Funded Warrants”) in a private placement transaction (the “Private Placement”). The purchase price per share of Common Stock is $68.00 per share (the “Purchase Price”) and the purchase price for the Pre-Funded Warrants is $67.99, which equals the Purchase Price minus the $0.01 exercise price per Pre-Funded”

Cottonwood Communities, Inc. issued 194,127 shares of preferred stock to accredited investors for aggregate proceeds of $1,918,200.

“During the period from September 29, 2025 through October 7, 2025, we issued and sold 194,127 shares of Series A Convertible Preferred Stock in the Series A Convertible Private Offering and received aggregate proceeds of $1,918,200.”

Quantum Computing Inc. issued 37,183,937 shares of common stock for approximately $750 million.

“stock, par value $0.0001 per share (the “Common Stock”). The closing of the Placement occurred on October 8, 2025. The Placement resulted in gross proceeds of approximately $750 million before deducting placement agent commissions and other offering expenses. The issuance of the Placement Shares was not registered under the Securities Act of 1933, as amended”

Vireo Growth Inc. issued common stock to several holders (the 'Noteholders') of those certain 13% Senior Secured Convertible Notes due December 7, 2026 for at a deemed price per share of $0.54.

“approximately 86% of the total outstanding Notes. The consideration will be paid in the form of the Company’s subordinate voting shares at closing at a deemed price per share of $0.54 (the “Shares”). The purchases are expected to close by October 31, 2025, and are subject to approval by the Canadian Stock Exchange. The Notes accrue interest at a rate equal to”

Vicarious Surgical Inc. issued Series B common warrants (the “Series B Common Warrants”) to purchase an aggregate of 1,150,000 shares of Common Stock of warrant to institutional investor for aggregate gross proceeds from the Offerings of approximately $5.9 million.

“Form 8-K as the “Offerings.” The Company expects the Offerings to close on or about October 9, 2025 and to receive aggregate gross proceeds from the Offerings of approximately $5.9 million, excluding any proceeds that may be received upon the exercise of the Common Warrants and before deducting placement agent fees and other offering expenses payable by the”

Vicarious Surgical Inc. issued Series A common warrants (the “Series A Common Warrants”) to purchase an aggregate of 1,150,000 shares of Common Stock of warrant to institutional investor for aggregate gross proceeds from the Offerings of approximately $5.9 million.

“Form 8-K as the “Offerings.” The Company expects the Offerings to close on or about October 9, 2025 and to receive aggregate gross proceeds from the Offerings of approximately $5.9 million, excluding any proceeds that may be received upon the exercise of the Common Warrants and before deducting placement agent fees and other offering expenses payable by the”

Vicarious Surgical Inc. issued pre-funded warrants (the “Pre-Funded Warrants”) to purchase up to 561,700 shares of Common Stock of warrant to institutional investor for aggregate gross proceeds from the Offerings of approximately $5.9 million.

“Form 8-K as the “Offerings.” The Company expects the Offerings to close on or about October 9, 2025 and to receive aggregate gross proceeds from the Offerings of approximately $5.9 million, excluding any proceeds that may be received upon the exercise of the Common Warrants and before deducting placement agent fees and other offering expenses payable by the”

Vicarious Surgical Inc. issued 588,300 shares of common stock to institutional investor for aggregate gross proceeds from the Offerings of approximately $5.9 million.

“Form 8-K as the “Offerings.” The Company expects the Offerings to close on or about October 9, 2025 and to receive aggregate gross proceeds from the Offerings of approximately $5.9 million, excluding any proceeds that may be received upon the exercise of the Common Warrants and before deducting placement agent fees and other offering expenses payable by the”

Transcode Therapeutics, Inc. issued 223.7337 shares of Series B Non-Voting Preferred Stock of preferred stock to DEFJ, LLC for aggregate purchase price of approximately $25 million, consisting of $20 million cash and a $5 million promissory note.

“the Company entered into an Investment Agreement (the “Investment Agreement”) with DEFJ. Pursuant to the Investment Agreement, DEFJ agreed to purchase, and the Company agreed to issue and sell in a private placement, an aggregate of 223.7337 shares of Series B Non-Voting Preferred Stock, par value $0.0001 per share (the “Series B Preferred Stock” and, together with the Series A Preferred Stock, the “Preferred Stock”), for a price per share of $ 11.1740, for an aggregate purchase price of approximately $25 million, consisting of a cash subscription amount of approximately $20 million and a promissory note (the “Promissory Note”) in the aggregate principal amount of approximately $5 million (the “Investment”).”

Transcode Therapeutics, Inc. issued 1,152.9568 shares of Series A Non-Voting Convertible Preferred Stock of preferred stock to DEFJ, LLC for issued in exchange for 100% membership interests of ABCJ, LLC.

“into a Membership Interest Purchase Agreement (the “Purchase Agreement”) with DEFJ, LLC, a Delaware limited liability company (“DEFJ”), pursuant to which the Company acquired 100% of the issued and outstanding membership interests of ABCJ, LLC, a Delaware limited liability company (“ABCJ”) (such transaction, the “Acquisition”). Prior to the Acquisition,”

Transcode Therapeutics, Inc. issued 83,285 shares of the Company’s common stock of common stock to DEFJ, LLC for issued in exchange for 100% membership interests of ABCJ, LLC.

“into a Membership Interest Purchase Agreement (the “Purchase Agreement”) with DEFJ, LLC, a Delaware limited liability company (“DEFJ”), pursuant to which the Company acquired 100% of the issued and outstanding membership interests of ABCJ, LLC, a Delaware limited liability company (“ABCJ”) (such transaction, the “Acquisition”). Prior to the Acquisition,”

Healthcare Triangle, Inc. issued warrant to holders of the Company’s warrants to purchase shares of the Company’s common stock issued on February 28, 2025.

“the information contained in Item 1.01 of this Current Report on Form 8-K and Exhibit 10.1 to this Current Report on Form 8-K regarding the Existing Warrants are incorporated herein by reference”

Healthcare Triangle, Inc. issued an aggregate of up to 1,429,528 shares of Common Stock of common stock to holders of the Company’s warrants to purchase shares of the Company’s common stock issued on February 28, 2025 for at the reduced exercise price of $2.00 per share.

“the Holders of the Existing Warrants agreed to exercise for cash the Existing Warrants to purchase an aggregate of up to 1,429,528 shares of Common Stock (the “Existing Warrant Shares”), at the reduced exercise price of $2.00 per share”

Healthcare Triangle, Inc. issued 2.0% of the number of New Warrant Shares issued in the offering of warrant to WallachBeth Capital, LLC.

“the Company agreed to issue to the designees of the Financial Advisor, warrants (“Advisor Warrants”) to purchase shares of Common Stock (the “Advisor Warrant Shares”), equal to approximately 2.0% of the number of New Warrant Shares issued in the offering”

Healthcare Triangle, Inc. issued up to 1,429,528 shares of Common Stock of warrant to holders of the Company’s warrants to purchase shares of the Company’s common stock issued on February 28, 2025 for aggregate gross proceeds of approximately $2.85 million.

“were consummated on October 2, 2025, October 3, 2025, and October 8, 2025 (together the “Closing Date”). The Company received aggregate gross proceeds of approximately $2.85 million, before deducting advisory fees and other expenses payable by the Company. In consideration of the Holders’ immediate exercise of the Existing Warrants in accordance with the”

NETLIST INC issued warrant to the Purchasers (as defined in the Purchase Agreement) for reduction of the exercise price of the June 2025 Warrants to the lesser of $0.60 and the lowest VWAP of the shares of common stock on any trading day during the.

“The Purchasers also agreed to amend certain issued and outstanding Common Stock Purchase Warrants held by such Purchasers (the “June 2025 Warrants”) previously issued pursuant to that certain Securities Purchase Agreement, dated as of June 24, 2025 (the “June 2025 Purchase Agreement”) to, among other things, revise certain anti-dilution provisions in the June 2025 Warrants in exchange for the reduction of the exercise price of the June 2025 Warrants to the lesser of $0.60 and the lowest VWAP of the shares of common stock on any trading day during the period commencing on the date of execution of the definitive agreements for the Offering and including, the fourth trading day immediately following the closing of the Offering”

NETLIST INC issued 28,571,432 shares of Common Stock of warrant to certain investors for $0.70 per Share and accompanying Warrants.

“the Company agreed to issue and sell to the Purchasers in a registered offering (the “Offering”) an aggregate of (i) 14,285,716 shares (the “Shares”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”), and (ii) Common Stock Purchase Warrants (the “Warrants”) to purchase up to an aggregate of 28,571,432 shares of Common Stock (the “Warrant Shares”) at a combined purchase price of $0.70 per Share and accompanying Warrants”

NETLIST INC issued 14,285,716 shares of common stock to certain investors for $0.70 per Share and accompanying Warrants.

“the Company agreed to issue and sell to the Purchasers in a registered offering (the “Offering”) an aggregate of (i) 14,285,716 shares (the “Shares”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”), and (ii) Common Stock Purchase Warrants (the “Warrants”) to purchase up to an aggregate of 28,571,432 shares of Common Stock (the “Warrant Shares”) at a combined purchase price of $0.70 per Share and accompanying Warrants”

RYVYL Inc. issued 50,000 shares of Series C Convertible Preferred Stock of preferred stock to the Investors named in the Purchase Agreement for $0.40 per share for gross proceeds of up to $5,000,000.

“the Company sold an aggregate of 50,000 shares of its Series C convertible preferred stock, par value $0.001 per share (the “Series C Preferred Stock”)to the Investors in a private placement (the “PIPE financing”), which was closed on October 7, 2025. Each share of Series C Preferred Stock was sold at a purchase price of $0.40 per share to the Investors for a gross proceeds of up to $5,000,000 to the Company, before the offering expenses.”

Blackstone Real Estate Income Trust, Inc. issued 513,844 of common stock to accredited investors for aggregate consideration of approximately $7.2 million.

“On October 1, 2025, Blackstone Real Estate Income Trust, Inc. (the “Company”) sold unregistered shares of the Company’s common stock (the “Shares”) for aggregate consideration of approximately $7.2 million.”

Jade Biosciences, Inc. issued pre-funded warrants to purchase an aggregate of 1,402,092 shares of common stock of warrant to institutional and accredited investors for purchase price of $9.1399 per pre-funded warrant.

“million, (i) an aggregate of 13,368,164 shares (the “Common Shares”) of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), at a price per share of $9.14, and (ii) pre-funded warrants (the “Pre-Funded Warrants”) to purchase an aggregate of 1,402,092 shares of Common Stock at a purchase price of $9.1399 per Pre-Funded Warrant,”

Jade Biosciences, Inc. issued 13,368,164 shares of common stock of common stock to institutional and accredited investors for aggregate purchase price of approximately $135 million.

““Closing”) is expected to occur on October 8, 2025. Pursuant to the Purchase Agreement, the Purchasers have agreed to purchase, for an aggregate purchase price of approximately $135 million, (i) an aggregate of 13,368,164 shares (the “Common Shares”) of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), at a price per share of $9.14, and”

SmartKem, Inc. issued 10,000 shares of common stock to a vendor for as consideration for consulting services.

“On July 1, 2025, the Company issued 10,000 shares of Common Stock to a vendor as consideration for consulting services.”

SmartKem, Inc. issued up to 500,000 shares of common stock to two consulting firms for in consideration for such services.

“On October 7, 2025, SmartKem, Inc. (the “Company”) entered into agreements with two consulting firms to provide investor relations related services to the Company, and in consideration for such services, agreed to issue up 500,000 shares (the “Shares”) of common stock of the Company”

FLYEXCLUSIVE INC. issued 432,099 shares of common stock to Volato Group, Inc. for $2.1 million.

“The Company has elected to pay all of the $2.1 million in shares of its Class A common stock and will issue an aggregate of 432,099 shares upon the receipt of all necessary approvals and conditions.”

C2 Blockchain, Inc. issued 10,000,000 shares of common stock to accredited investor for $0.01 per share.

“On or about October 3, 2025, the Company entered into a subscription agreement with an accredited investor pursuant to which it issued 10,000,000 shares of its restricted common stock at a purchase price of $0.01 per share, for gross proceeds of $100,000 (the "First Tranche").”

C2 Blockchain, Inc. issued 750,000 shares of common stock to accredited investor for $0.02 per share.

“On or about September 10, 2025, the Company entered into a subscription agreement with an accredited investor pursuant to which it issued 750,000 shares of its restricted common stock at a purchase price of $0.02 per share, for gross proceeds of $15,000.”

TREASURE GLOBAL INC issued common stock to two Malaysian individuals, Chuah Su Chen and the Company’s director Chan Meng Chun for $1.16 per share.

“On October 7, 2025, Treasure Global Inc (the “Company”) entered into a subscription agreement (the “Agreement”) with two Malaysian individuals, Chuah Su Chen and the Company’s director Chan Meng Chun (together with Chuah Su Chen, the “Investors”). Subject to the terms and conditions set forth in the Agreement, the Company desires to issue and sell to each Investor, and each Investor desires to subscribe for, an aggregate amount of USD200,000.00 in the Company for the allotment and issuance of common stock of the Company (“the Shares”) for the purchase price of $1.16 per share”

EQT Exeter Real Estate Income Trust, Inc. issued 252,945.525 Class A-II shares of common stock of common stock to accredited investors for $10.61 per share.

“On October 1, 2025, the Company issued 252,945.525 Class A-II shares of common stock at a price per share of $10.61 to accredited investors in a private placement for an aggregate purchase price of approximately $2.68 million.”

EQT Exeter Real Estate Income Trust, Inc. issued 5,603.360 shares of Class A-II common stock of common stock to accredited investors for $59.17 thousand aggregate.

“On September 10, 2025, the Company issued 10,163.669 shares of Class A-I common stock at a price per share of $10.57 for an aggregate purchase price of approximately $0.11 million and 5,603.360 shares of Class A-II common stock at a price per share of $10.56 for an aggregate purchase price of approximately $59.17 thousand.”

EQT Exeter Real Estate Income Trust, Inc. issued 10,163.669 shares of Class A-I common stock of common stock to accredited investors for $0.11 million aggregate.

“On September 10, 2025, the Company issued 10,163.669 shares of Class A-I common stock at a price per share of $10.57 for an aggregate purchase price of approximately $0.11 million and 5,603.360 shares of Class A-II common stock at a price per share of $10.56 for an aggregate purchase price of approximately $59.17 thousand.”

EQT Exeter Real Estate Income Trust, Inc. issued 221.786 shares of Class E common stock of common stock to two of the Company's independent directors for $11.25 per share.

“On September 10, 2025, EQT Exeter Real Estate Income Trust, Inc. (the “Company”) issued 221.786 shares of Class E common stock at a price per share of $11.25 to two of the Company’s independent directors, for an aggregate purchase price of approximately $2.50 thousand.”

Fortress Net Lease REIT issued 4,983,082 common shares of common stock for gross proceeds of approximately $51.3 million.

“Fortress Net Lease REIT (the “Company” or “we”) issued and sold an aggregate of 4,983,082 common shares for gross proceeds of approximately $51.3 million, based on net asset value per share of the applicable class of common shares as of August 31, 2025.”

LandBridge Co LLC issued common stock to 1918 Ranch & Royalty, LLC for $41.7 million in units.

“Texas, and certain related assets (the “Acquisition”) for an aggregate purchase price of $250.0 million, consisting of approximately $208.3 million in cash and approximately $41.7 million in units representing limited liability company interests in OpCo (together with an equal number of Class B shares representing limited liability company interests in the Company”

North Haven Net REIT issued 1,334,355 common shares of common stock to accredited investors for approximately $27.3 million.

“on October 1, 2025, the Company sold an aggregate of 1,334,355 common shares (the “Shares”) for aggregate consideration of approximately $27.3 million”

FORTRESS CREDIT REALTY INCOME TRUST issued 1,615,842 common shares of common stock to accredited investors for gross proceeds of approximately $32.6 million.

“Fortress Credit Realty Income Trust (the “Company” or “we”) issued and sold an aggregate of 1,615,842 common shares for gross proceeds of approximately $32.6 million, based on net asset value per share of the applicable class of common shares as of August 31, 2025”